PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30924641-2	2019	p300/CBP is composed of a number of domains including a HAT domain, which is inhibited by the small molecule A-485, and an acetyl-lysine binding bromodomain, which was recently found to be selectively antagonized by the small molecule I-CBP112.	N(alpha)-acetyllysine	123-136	E1A binding protein p300	Homo sapiens	0-4	
30962627-3	2019	Here, we identify acetyl-lysine competitive inhibitors targeting the bromodomains of coactivators CREB (cyclic-AMP response element binding protein) binding protein (CBP) and E1A binding protein of 300 kDa (EP300) as potent enhancers of reprogramming.	N(alpha)-acetyllysine	18-31	E1A binding protein p300	Homo sapiens	175-205	
30962627-3	2019	Here, we identify acetyl-lysine competitive inhibitors targeting the bromodomains of coactivators CREB (cyclic-AMP response element binding protein) binding protein (CBP) and E1A binding protein of 300 kDa (EP300) as potent enhancers of reprogramming.	N(alpha)-acetyllysine	18-31	E1A binding protein p300	Homo sapiens	207-212	
34199844-3	2021	CBP and p300 are critical ER co-activators and their acetyltransferase (KAT) domain and acetyl-lysine binding bromodomain (BD) represent tractable drug targets, but whether CBP/p300 inhibitors can effectively suppress ER signaling remains unclear.	N(alpha)-acetyllysine	88-101	E1A binding protein p300	Homo sapiens	8-12